Caplin Point Laboratories Share Price

Conference Call with Caplin Point Laboratories Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 week ago

Pharmaceuticals company Caplin Point Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 600.16 crore, representing a YoY increase of 19.4% compared to Rs 502.45 crore in Q4FY25 and a QoQ growth of 10.6% from Rs 542.77 crore in Q3FY26. Total Income for the quarter was Rs 628.52 crore, reflecting a YoY growth of 19.0% as against Rs 528.19 crore and a 9.0% increase QoQ from Rs 576.45 crore. Profit Before Tax (PBT) for Q4FY26 reached Rs 213.44 crore, up 20.8% YoY from Rs 176.67 crore and up 4.7% QoQ from Rs 203.89 crore in Q3FY26. Net Profit for the quarter (PAT) stood at Rs 172.88 crore, marking a 19.0% increase YoY compared to Rs 145.28 crore and a 4.2% increase QoQ from Rs 165.86 crore. For the full year ended March 31, 2026, Revenue from Operations was Rs 2,187.19 crore, a growth of 12.9% YoY from Rs 1,937.47 crore in FY25. Annual Total Income for FY26 was Rs 2,302.73 crore, showing a 13.2% increase over Rs 2,033.90 crore in FY25. Annual Net Profit (PAT) for FY26 stood at Rs 649.73 crore, registering a 20.1% growth from Rs 541.09 crore in FY25. Earnings Per Share (EPS) for Q4FY26 was Rs 22.38 (Basic), compared to Rs 18.75 in Q4FY25. For FY26, Basic EPS reached Rs 84.36, up from Rs 70.57 in FY25. Standalone Financial Highlights: Revenue from Operations for Q4FY26 was Rs 191.36 crore, reflecting a 10.2% YoY growth from Rs 173.61 crore in Q4FY25 and a 1.1% QoQ increase from Rs 189.22 crore in Q3FY26. Total Income for the quarter reached Rs 252.44 crore, compared to Rs 214.86 crore in Q4FY25 and Rs 220.95 crore in Q3FY26. Profit Before Tax (PBT) for Q4FY26 stood at Rs 137.72 crore, a 25.0% increase YoY as against Rs 110.16 crore and a 17.7% increase QoQ from Rs 117.01 crore. Net Profit (PAT) for the quarter was Rs 109.50 crore, up 26.6% YoY from Rs 86.50 crore and up 25.5% QoQ from Rs 87.28 crore. For FY26, Standalone Revenue from Operations was Rs 738.33 crore, compared to Rs 752.41 crore in FY25. Annual Standalone Net Profit (PAT) for FY26 was Rs 396.58 crore, representing a 16.8% increase YoY from Rs 339.49 crore. Business Highlights: Geographical Segment Performance: Rest of the World: This segment recorded a revenue of Rs 470.25 crore in Q4FY26 and Rs 1,733.79 crore For FY26. Segment results (PBT) for the year reached Rs 631.20 crore. USA: This segment generated a revenue of Rs 129.91 crore in Q4FY26 and Rs 453.40 crore For FY26. Segment results (PBT) for the year stood at Rs 56.05 crore. Interim Dividend: The Board of Directors declared an Interim Dividend of Rs 4.00 (200%) per equity share of face value Rs 2 each for the financial year ended March 31, 2026. Caplin Steriles USA Inc (CSU) Performance: CSU completed its first full year of operations with approximately USD 11 million in revenue and 26.2% EBITDA, achieving profitability and self-sustaining cash flow within its first year. CSU has launched 30 products to date with plans to launch 15 more in the current year. Product Approvals and Pipeline: The company received 10 ANDA approvals in FY26 and acquired 15 ANDAs from third parties, bringing the total ANDA tally to 59, an increase of 25 ANDAs over FY25. In Mexico, the company received approvals for 25 products with a pipeline of over 120 products to be filed within 18 months. Capacity Expansion: The company is expanding its IV Bag line capacity to 3X its current size. Construction of the COL-II facility is expected to be completed by December 2026, which will house 5 Injectable, Ophthalmic, and BFS lines. Strategic Growth and Capex: Caplin Point has allocated an enhanced Capex budget of approximately Rs 1,000 + crore for investment projects, with about 50% nearing completion. Latin America Update: The company entered the Brand Marketing CNS segment in three Latin American markets, with plans to expand to two more in 2027. Labour Code Impact: The company assessed the implications of the New Labour Codes, resulting in an increase in employee benefit obligations (gratuity and compensated absences) aggregating to Rs 1.39 crore (Consolidated) and Rs 0.84 crore (Standalone). C.C. Paarthipan, Chairman, said: The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also. Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth. During the year, we made significant investments in building future capabilities — across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and BlowFill-Seal technology, positions us well for the next phase of growth. Importantly, these investments are being made while maintaining strong cash flows and a robust balance sheet. We remain debt-free and will continue to remain so. We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations — an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments. As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position. While we remain optimistic about the opportunities ahead, we will continue to approach growth with prudence and discipline, staying aligned with our core principles of sustainable and profitable expansion. I would like to thank our employees for their dedication, our partners for their continued trust, and our shareholders for their unwavering support. Result PDF

• Trendlyne
• 1 week ago

High growth levers in development as the current base supports industry level growth

• Business Line
• 1 month 1 week ago